Ovid Therapeutics Inc.

0.34
0.03 (9.78%)
At close: Apr 02, 2025, 3:59 PM
0.36
5.15%
After-hours: Apr 02, 2025, 07:46 PM EDT

Company Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States.

The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies.

It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder.

The company has license and collaboration agreements with Healx, AstraZeneca AB, H.

Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc.

The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc.
Ovid Therapeutics Inc. logo
Country United States
IPO Date May 5, 2017
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.

Contact Details

Address:
1460 Broadway
New York, New York
United States
Website https://www.ovidrx.com

Stock Details

Ticker Symbol OVID
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001636651
CUSIP Number 690469101
ISIN Number US6904691010
Employer ID 46-5270895
SIC Code 2834

Key Executives

Name Position
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. Chief Executive Officer & Chairman
Meg Alexander President & Chief Operating Officer
Dr. Dirk Haasner Senior Vice President of Global Manufacturing & CMC QA
Dr. Julia Tsai Ph.D. Senior Vice President of Clinical Development
Dr. Manal Morsy M.B.A., M.D., PH.D. Chief Regulatory Officer
Dr. Toshiya Nishi D.V.M. Head of Epilepsy Research
Jeffrey A. Rona Chief Business and Financial Officer
Tom Parry Vice President of Research and Early Development
Victoria Fort Senior Vice President of Corporate Affairs & Corporate Strategy
Zhong Zhong Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Mar 11, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 05, 2025 8-K Current Report
Mar 04, 2025 4 Filing
Mar 04, 2025 3 Filing
Feb 28, 2025 4 Filing
Feb 28, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing